Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma

Junyu Li, Shaji Abraham, Liang Cheng, Frank Witzmann, Michael Koch, Jun Xie, Munazzah Rahman, Sulma I. Mohammed

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Identification of reliable non-invasive markers for the detection of invasive phenotype of urothelial carcinoma is needed. This study characterizes and compares protein expression profiles of adjacent non-neoplastic urothelium and invasive urothelial carcinoma to identify biomarkers for early detection of de novo bladder cancer. Differences in protein expression between adjacent non-neoplastic and high-grade, stage T4, grade 3 invasive urothelial carcinoma tissues were investigated using 2-DE, MALDI-TOF-MS, and data processing. Ingenuity Pathway Analysis (IPA) was applied to examine the biological mechanisms represented by the altered proteins. The 2-DE of the adjacent non-neoplastic urothelium and invasive urothelial carcinoma showed reproducibly similar proteomic mapping for each group distinguishing adjacent non-neoplastic urothelium from invasive urothelial carcinoma, Twenty-one proteins were altered in expression and one of these proteins, Choroideremia-like protein (CHML) was significantly overexpressed (p<0.005) and therefore was analyzed further using IHC and Western blot. Urothelial carcinoma presented an elevated expression of CHML but not adjacent non-neoplastic or normal bladder tissues. IPA revealed the involvement of CHML in cell morphology, cellular assembly, and organization. Further investigation is warranted to elucidate the biological significance of CHML and to validate its role as a biomarker for early detection of invasive urothelial carcinoma de novo.

Original languageEnglish
Pages (from-to)78-89
Number of pages12
JournalProteomics - Clinical Applications
Volume2
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Biomarkers
Proteomics
Choroideremia
Carcinoma
Urothelium
Proteins
Tissue
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Urinary Bladder Neoplasms
Urinary Bladder
Western Blotting
Phenotype

Keywords

  • Biomarker discovery
  • Bladder
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma. / Li, Junyu; Abraham, Shaji; Cheng, Liang; Witzmann, Frank; Koch, Michael; Xie, Jun; Rahman, Munazzah; Mohammed, Sulma I.

In: Proteomics - Clinical Applications, Vol. 2, No. 1, 01.2008, p. 78-89.

Research output: Contribution to journalArticle

@article{c52b4bb79a76467e9f4811db9df1eb70,
title = "Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma",
abstract = "Identification of reliable non-invasive markers for the detection of invasive phenotype of urothelial carcinoma is needed. This study characterizes and compares protein expression profiles of adjacent non-neoplastic urothelium and invasive urothelial carcinoma to identify biomarkers for early detection of de novo bladder cancer. Differences in protein expression between adjacent non-neoplastic and high-grade, stage T4, grade 3 invasive urothelial carcinoma tissues were investigated using 2-DE, MALDI-TOF-MS, and data processing. Ingenuity Pathway Analysis (IPA) was applied to examine the biological mechanisms represented by the altered proteins. The 2-DE of the adjacent non-neoplastic urothelium and invasive urothelial carcinoma showed reproducibly similar proteomic mapping for each group distinguishing adjacent non-neoplastic urothelium from invasive urothelial carcinoma, Twenty-one proteins were altered in expression and one of these proteins, Choroideremia-like protein (CHML) was significantly overexpressed (p<0.005) and therefore was analyzed further using IHC and Western blot. Urothelial carcinoma presented an elevated expression of CHML but not adjacent non-neoplastic or normal bladder tissues. IPA revealed the involvement of CHML in cell morphology, cellular assembly, and organization. Further investigation is warranted to elucidate the biological significance of CHML and to validate its role as a biomarker for early detection of invasive urothelial carcinoma de novo.",
keywords = "Biomarker discovery, Bladder, Urothelial carcinoma",
author = "Junyu Li and Shaji Abraham and Liang Cheng and Frank Witzmann and Michael Koch and Jun Xie and Munazzah Rahman and Mohammed, {Sulma I.}",
year = "2008",
month = "1",
doi = "10.1002/prca.200780027",
language = "English",
volume = "2",
pages = "78--89",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma

AU - Li, Junyu

AU - Abraham, Shaji

AU - Cheng, Liang

AU - Witzmann, Frank

AU - Koch, Michael

AU - Xie, Jun

AU - Rahman, Munazzah

AU - Mohammed, Sulma I.

PY - 2008/1

Y1 - 2008/1

N2 - Identification of reliable non-invasive markers for the detection of invasive phenotype of urothelial carcinoma is needed. This study characterizes and compares protein expression profiles of adjacent non-neoplastic urothelium and invasive urothelial carcinoma to identify biomarkers for early detection of de novo bladder cancer. Differences in protein expression between adjacent non-neoplastic and high-grade, stage T4, grade 3 invasive urothelial carcinoma tissues were investigated using 2-DE, MALDI-TOF-MS, and data processing. Ingenuity Pathway Analysis (IPA) was applied to examine the biological mechanisms represented by the altered proteins. The 2-DE of the adjacent non-neoplastic urothelium and invasive urothelial carcinoma showed reproducibly similar proteomic mapping for each group distinguishing adjacent non-neoplastic urothelium from invasive urothelial carcinoma, Twenty-one proteins were altered in expression and one of these proteins, Choroideremia-like protein (CHML) was significantly overexpressed (p<0.005) and therefore was analyzed further using IHC and Western blot. Urothelial carcinoma presented an elevated expression of CHML but not adjacent non-neoplastic or normal bladder tissues. IPA revealed the involvement of CHML in cell morphology, cellular assembly, and organization. Further investigation is warranted to elucidate the biological significance of CHML and to validate its role as a biomarker for early detection of invasive urothelial carcinoma de novo.

AB - Identification of reliable non-invasive markers for the detection of invasive phenotype of urothelial carcinoma is needed. This study characterizes and compares protein expression profiles of adjacent non-neoplastic urothelium and invasive urothelial carcinoma to identify biomarkers for early detection of de novo bladder cancer. Differences in protein expression between adjacent non-neoplastic and high-grade, stage T4, grade 3 invasive urothelial carcinoma tissues were investigated using 2-DE, MALDI-TOF-MS, and data processing. Ingenuity Pathway Analysis (IPA) was applied to examine the biological mechanisms represented by the altered proteins. The 2-DE of the adjacent non-neoplastic urothelium and invasive urothelial carcinoma showed reproducibly similar proteomic mapping for each group distinguishing adjacent non-neoplastic urothelium from invasive urothelial carcinoma, Twenty-one proteins were altered in expression and one of these proteins, Choroideremia-like protein (CHML) was significantly overexpressed (p<0.005) and therefore was analyzed further using IHC and Western blot. Urothelial carcinoma presented an elevated expression of CHML but not adjacent non-neoplastic or normal bladder tissues. IPA revealed the involvement of CHML in cell morphology, cellular assembly, and organization. Further investigation is warranted to elucidate the biological significance of CHML and to validate its role as a biomarker for early detection of invasive urothelial carcinoma de novo.

KW - Biomarker discovery

KW - Bladder

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=38949122474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949122474&partnerID=8YFLogxK

U2 - 10.1002/prca.200780027

DO - 10.1002/prca.200780027

M3 - Article

VL - 2

SP - 78

EP - 89

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 1

ER -